Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tanshinone IIA sulfonate sodium (Tanshinone IIA sodium sulfonate) 是从丹参中提取的丹参酮IIA 的水溶性衍生物,是SOCE 抑制剂,用于心血管疾病的研究。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 255 | 现货 | ||
10 mg | ¥ 413 | 现货 | ||
25 mg | ¥ 663 | 现货 | ||
50 mg | ¥ 972 | 现货 | ||
100 mg | ¥ 1,430 | 现货 | ||
500 mg | ¥ 3,580 | 现货 |
产品描述 | Tanshinone IIA sulfonate sodium (Tanshinone IIA sodium sulfonate) is a water-soluble derivative of tanshinone IIA extracted from Savia miltiorrhiza; a potent negative allosteric modulator of the human purinergic receptor P2X7. Tanshinone IIA sulfonate sodium (12.5 μM) inhibits hypoxia-induced PKG and PPAR-γ downregulation in PASMCs and distal pulmonary arteries of rats. |
靶点活性 | CYP3A4:6.377 μM |
体外活性 | Sodium Tanshinone IIA sulfonate (12.5 μM) inhibits hypoxia-induced PKG and PPAR-γ downregulation in PASMCs and distal pulmonary arteries of rats. The suppressive effects of Sodium Tanshinone IIA sulfonate on TRPC1 and TRPC6 expression in hypoxic PASMCs can be prevented by specific knockdown PKG or PPAR-γ. The suppressive effects of Sodium Tanshinone IIA sulfonate on basal calcium concentration and SOCE in hypoxic PASMCs can be reversed by specific knockdown of PKG or PPAR-γ. PKG-PPAR-γ signaling axis participates in the suppressive effects of Sodium Tanshinone IIA sulfonate on proliferation in hypoxic PASMCs. PPAR-γ agonist promotes the protective role of Sodium Tanshinone IIA sulfonate on basal [Ca2+]i and SOCE in hypoxic PASMCs[2]. Sodium tanshinone IIA sulfonate inhibits the activity of CYP3A4 by the HLMs and CYP3A4 isoform in a dose-dependent manner. The KM and Vmax values of STS are 54.8±14.6 μM and 0.9±0.1 nmol/mg protein/min, respectively, for the HLMs and 7.5±1.4 μM and 6.8±0.3 nmol/nmol P450/min, respectively, for CYP3A4. CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, and CYP2C19 show minimal or no effects on the metabolism of STS[3]. Sodium Tanshinone IIA sulfonate inhibits the activity of CYP3A4 in the HLMs and CYP3A4 isoform in a dose-dependent manner. Sodium Tanshinone IIA sulfonate primarily inhibits the activities of CYP3A4 in vitro, and Sodium Tanshinone IIA sulfonate has the potential to perpetrate drug-drug interactions with other CYP3A4 substrates[4]. |
体内活性 | Sodium Tanshinone IIA sulfonate (10 mg/kg, 20 mg/kg) and Donepezil shorten escape latency, increase crossing times of the original position of the platform, and increase the time spent in the target quadrant. Sodium Tanshinone IIA sulfonate decreases the activity of acetylcholinesterase (AChE) as well as increases the activity of choline acetyltransferase (ChAT) in the hippocampus and cortex of SCOP-treated mice. Sodium Tanshinone IIA sulfonate increases the activity of superoxide dismutase (SOD) and decreases the levels of malondialdehyde (MDA) and reactive oxygen species (ROS) in hippocampus and cortex[1]. Sodium Tanshinone IIA sulfonate prevention (30 mg/kg/day) alleviates hypoxia-induced characteristic changes in chronic hypoxia PH rat model[2]. Sodium Tanshinone IIA sulfonate (20, 10, and 5 mg/kg, i.p.) effectively prevents peritoneal adhesion without affecting anastomotic healing in the rats. Compared with the adhesion model group, the Sodium Tanshinone IIA sulfonate-treated groups show increased peritoneal lavage fluid tPA activity and tPA/PAI-1 ratio in the ischemic tissues with loared TGF-β1 and collagen I expressions in the ischemic tissues[5] |
别名 | 丹参酮IIA磺酸盐, 丹参酮IIA-磺酸钠, Tanshinone IIA sulfonate, Sodium Tanshinone IIA sulfonate, Tanshinone IIA sodium sulfonate, sodium |
分子量 | 396.39 |
分子式 | C19H17O6S·Na |
CAS No. | 69659-80-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (126.14 mM), The compound is unstable in solution. Please use soon.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5228 mL | 12.6138 mL | 25.2277 mL | 63.0692 mL |
5 mM | 0.5046 mL | 2.5228 mL | 5.0455 mL | 12.6138 mL | |
10 mM | 0.2523 mL | 1.2614 mL | 2.5228 mL | 6.3069 mL | |
20 mM | 0.1261 mL | 0.6307 mL | 1.2614 mL | 3.1535 mL | |
50 mM | 0.0505 mL | 0.2523 mL | 0.5046 mL | 1.2614 mL | |
100 mM | 0.0252 mL | 0.1261 mL | 0.2523 mL | 0.6307 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tanshinone IIA sulfonate sodium 69659-80-9 Membrane transporter/Ion channel Metabolism Neuroscience Calcium Channel P450 CaMK CRAC Channel Calcium release-activated channels 丹参酮IIA磺酸盐 丹参酮IIA-磺酸钠 Tanshinone IIA sulfonate Sodium Tanshinone IIA sulfonate Ca2+ release-activated Ca2+ channels Tanshinone IIA sodium sulfonate inhibit Inhibitor sodium inhibitor